Cargando…

Drug Resistance in Hematological Malignancies

Detalles Bibliográficos
Autores principales:	Auberger, Patrick, Tamburini-Bonnefoy, Jerome, Puissant, Alexandre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503602/ https://www.ncbi.nlm.nih.gov/pubmed/32847013 http://dx.doi.org/10.3390/ijms21176091

Ejemplares similares

Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics
por: Zhan, Fenghuang, et al.
Publicado: (2015)

Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies
por: Robert, Guillaume, et al.
Publicado: (2019)

Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders
por: Găman, Amelia Maria
Publicado: (2023)

Nursing in patients with hematological malignancies
por: Geres, Hana, et al.
Publicado: (2020)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

Immune Microenvironment in Hematologic Malignancies
por: Arandi, Nargess, et al.
Publicado: (2023)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells
por: Hamouda, Mohamed-Amine, et al.
Publicado: (2014)

The premier statistical report of hematologic malignancies in Korea
por: Kim, Hee-Je
Publicado: (2012)

The emerging role of Twist proteins in hematopoietic cells and hematological malignancies
por: Merindol, N, et al.
Publicado: (2014)

The emerging role of Twist proteins in hematopoietic cells and hematological malignancies
por: Merindol, N, et al.
Publicado: (2014)

Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview
por: Barbato, Alessandro, et al.
Publicado: (2020)

Accuracy of diagnosis and individualization of treatment: the way of treating hematologic malignancies
por: Liu, Dai-Hong
Publicado: (2020)

Preface of the Special Issue “COVID-19 Infection and Hematological Malignancies”
por: Chen, Mingyi, et al.
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

Chromosomal aberrations in hematological malignancies: A guide to the identification of novel oncogenes
por: Vundinti, Babu Rao, et al.
Publicado: (2011)

CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011)

Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice
por: Ma, Haiqing, et al.
Publicado: (2015)

For older adults with hematologic malignancies, a comprehensive geriatric assessment matters
por: Cordoba, Raul
Publicado: (2022)

Drug Design and Development for Rare Hematologic Diseases
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Ultrasound-assisted one-pot three-component synthesis of new isoxazolines bearing sulfonamides and their evaluation against hematological malignancies
por: Talha, Aicha, et al.
Publicado: (2021)

Patients with hematological malignancies admitted to intensive care units: new challenges for the intensivist
por: Torres, Viviane Bogado Leite, et al.
Publicado: (2015)

An interview with Dan L. Longo, Section Editor of the Malignant hematological diseases section
por: Longo, Dan L
Publicado: (2013)

Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies
por: Wiestner, Adrian
Publicado: (2022)

2018–2019 Drug Updates in Hematologic Malignancies
por: Held, Lauren
Publicado: (2020)

2019–2020 Drug Updates in Hematologic Malignancies
por: Finnes, Heidi D.
Publicado: (2021)

2020–2021 Drug Updates in Hematologic Malignancies
por: Hanna, Kirollos
Publicado: (2022)

2021–2022 Drug Updates in Hematologic Malignancies
por: Tobin, Jenni
Publicado: (2023)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies
por: Wang, Tao, et al.
Publicado: (2022)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next?
por: Gribben, John G., et al.
Publicado: (2020)

Dilemma Concerning the Differential Diagnosis of Hematological Malignancy and Bone Metastasis Arising from Lung Cancer
por: Kaira, Kyoichi
Publicado: (2022)

Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death
por: Robert, Guillaume, et al.
Publicado: (2009)

Why should we monitor for hematologic adverse drug reactions to oxcarbazepine?
por: Jang, Gwang Cheon
Publicado: (2019)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

Antifungal Resistance and Predictors of Response in Patients with Hematologic Malignancy
por: Wey, Shiuan (Shannon), et al.
Publicado: (2017)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4jl8l15rkpo74491h1jagnglvi